Gilead Sciences said on Thursday enrollments to test its cancer drug, magrolimab, on solid tumors had been paused globally, a week after the U.S. regulator put some studies.
Simulation models indicate that breast cancer screening and treatment were associated with a 58% reduction in mortality, based on data collected between 1975 and 2019.
Gilead Sciences said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company's blood cancer drug following increased risk of patient.